A Study of LY2599506 in Patients With Type 2 Diabetes

This study has been terminated.
(Terminated due to nonclinical safety findings)
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01024244
First received: December 1, 2009
Last updated: November 29, 2011
Last verified: November 2011

December 1, 2009
November 29, 2011
December 2009
July 2010   (final data collection date for primary outcome measure)
Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at 12 Weeks [ Time Frame: Baseline, 12 weeks ] [ Designated as safety issue: No ]
Change in HbA1c from baseline following 12 weeks of therapy (HbA1c at week 12 minus HbA1c at baseline). Study GMAH was terminated after enrolling 78 participants. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure is not presented.
Change in hemoglobin A1c from baseline to 12 week endpoint [ Time Frame: Baseline, 12 weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01024244 on ClinicalTrials.gov Archive Site
  • Change From Baseline in the QT Interval in Electrocardiogram (ECG) at 12 Weeks and 16 Weeks [ Time Frame: Baseline, 12 weeks, 16 weeks ] [ Designated as safety issue: Yes ]
    Measures the QT interval in the ECG. Study GMAH was terminated after enrolling 78 participants. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure was not analyzed.
  • Change From Baseline in the Homeostasis Model Assessment (HOMA2) Pancreatic Beta Cell Function (%B) at 12 Weeks and 16 Weeks [ Time Frame: Baseline, 12 weeks, 16 weeks ] [ Designated as safety issue: No ]
    HOMA2 is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady state pancreatic beta cell function (%B) as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100%. Study GMAH was terminated after enrolling 78 participants. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure was not calculated or analyzed.
  • Change From Baseline in the Homeostasis Model Assessment (HOMA2) of Insulin Sensitivity (%S) at 12 Weeks and 16 Weeks [ Time Frame: Baseline, 12 weeks, 16 weeks ] [ Designated as safety issue: No ]
    HOMA2 is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S), as percentages of a normal reference population (normal young adults). The normal reference population was set at 100%. Study GMAH was terminated after enrolling 78 participants. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure was not calculated or analyzed.
  • Change From Baseline in Triglycerides, Low-density Lipoprotein Cholesterol (LDL-C), High-density Lipoprotein Cholesterol (HDL-C), Non-HDL-C, Total Cholesterol, and Free Fatty Acids at 12 Weeks and 16 Weeks [ Time Frame: Baseline, 12 weeks, 16 weeks ] [ Designated as safety issue: Yes ]
    Fasting lipids were measured after an overnight fast. Lipids measured included triglycerides, HDL-C, LDL-C, non-HDL-C, total cholesterol, and free fatty acids. Study GMAH was terminated after enrolling 78 participants. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure is not presented.
  • Change From Baseline in the European Quality of Life -5 Dimension (EQ-5D) at 12 Weeks and 16 Weeks [ Time Frame: Baseline, 12 weeks, 16 weeks ] [ Designated as safety issue: No ]
    Assesses 5 health domains: mobility, self-care, usual activity, pain, and anxiety/depression with 3 options each. Total scores range from 5 (no problem) to 15 (more severe or frequent problems). An algorithm maps the 5 domain outcomes to a single index (0-1). A higher score indicates better perceived health state. Study GMAH was terminated after enrolling 78 participants. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure was not analyzed.
  • Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at 12 Weeks and 16 Weeks [ Time Frame: Baseline, 12 weeks, 16 weeks ] [ Designated as safety issue: Yes ]
    Change in SBP and DBP following 12 weeks of therapy (Week 12 SBP minus SBP at baseline; Week 12 DBP minus DBP at baseline) and 16 weeks of therapy (Week 16 SBPB minus SBP at baseline; Week 16 DBP minus DBP at baseline). Study GMAH was terminated after enrolling 78 participants. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure is not presented.
  • Number of Hypoglycemic Episodes During 12-Week Treatment Period and 4-week Follow-up Period [ Time Frame: Baseline through 16 weeks ] [ Designated as safety issue: Yes ]
    Hypoglycemia was defined as any time a participant feels s/he was experiencing a sign or symptom associated with hypoglycemia or had a blood glucose <70 mg/dL (3.9 mmol/L) even if it was not associated with signs or symptoms of hypoglycemia. Study GMAH was terminated after enrolling only 78 participants. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure is not presented.
  • Change From Baseline in Body Weight at 12 Weeks and 16 Weeks [ Time Frame: Baseline, 12 weeks, 16 weeks ] [ Designated as safety issue: No ]
    Weight was measured in the fasting state (with the exception of Visit 1) and after emptying the bladder. Participants were instructed to be lightly clothed and without shoes. Study GMAH was terminated after enrolling 78 participants. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure is not presented.
  • Change From Baseline in the Seven-Point Self-Monitored Blood Glucose (7-point SMBG) at 4 Weeks, 12 Weeks, and 16 Weeks [ Time Frame: Baseline, 4 weeks, 12 weeks, 16 weeks ] [ Designated as safety issue: No ]
    SMBG levels were measured at the following 7 timepoints during the day: fasting pre-breakfast, 2 hours post-breakfast, prior to lunch, 2 hours post-lunch, prior to dinner, 2 hours postdinner, and prior to bed. Study GMAH was terminated after enrolling only 78 participants. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure is not presented.
  • Percentage of Participants Requiring Dose Adjustments During the 12-week Treatment Period [ Time Frame: Baseline through 12 weeks ] [ Designated as safety issue: No ]
    Percentage of participants who required dose adjustments at the discretion of the investigator for participants with persistent blood glucose<70 milligrams per deciliter (mg/dL). Study GMAH was terminated after enrolling 78 participants. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure was not analyzed.
  • Percentage of Participants With Lipase and Amylase Measurements Above 2-fold Upper Limits of Normal (ULN) During the 12-week Treatment Period [ Time Frame: Baseline through 12 weeks ] [ Designated as safety issue: Yes ]
    Lipase and amylase concentrations were assessed. Amylase normal limits for males and females are 28-100 units per liter (U/L) (18-50 years), 28-120 U/L (50-60 years), and 28-150 U/L (60-70 years). Normal lipase limits for males and females are 0-100 U/L (18-50 years; 50-60 years) and 0-120 U/L (60-70 years). Study GMAH was terminated after enrolling only 78 participants. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure is not presented.
  • Percentage of Participants With Clinically-Significant Elevations of Alanine Aminotransferase/Serum Glutamate Pyruvate Transaminase (ALT/SGPT) During the 12-week Treatment Period and 4-week Follow-up Period [ Time Frame: Baseline through 12 weeks, Baseline through 16 weeks ] [ Designated as safety issue: Yes ]
    Clinically significant elevations of ALT/SGPT were considered ≥3 times the upper limit of normal (ULN). The percentage of participants above 2- and 5-fold ULN was not analyzed due to the early termination of the trial. The percentage of participants with ALT 3-fold ULN or higher is presented.
  • Change From Baseline in the Diabetes Treatment Satisfaction Questionnaire (DTSQ) at 12 Weeks and 16 Weeks [ Time Frame: Baseline, 12 weeks, 16 weeks ] [ Designated as safety issue: No ]
    DTSQ, an 8-item questionnaire, measures satisfaction with treatment, perceived frequency of hyperglycemia, and perceived frequency of hypoglycemia. Response options range from 6 (best case) to 0 (worst case). Total scores for treatment satisfaction range from 0-36. Higher scores indicate higher satisfaction. Study GMAH was terminated after enrolling 78 participants. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure was not analyzed.
  • Change From Baseline in the Adult Low Blood Sugar Survey (LBSS-33 Item Scale) at 12 Weeks and 16 Weeks [ Time Frame: Baseline, 12 weeks, 16 weeks ] [ Designated as safety issue: No ]
    Assesses 2 hypoglycemia domains, with each item score from 0 (never engages in behavior) to 4 (always engages in behavior): Behavioral (15 items; range 0-60) and Worry about hypoglycemia (18 items; range 0-72). Total score is the sum of both domains (range 0-132). Higher scores indicate greater negative impact. Study GMAH was terminated after enrolling 78 participants. Given the small sample size overall, and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading. As a result, this outcome measure was not analyzed.
  • Changes From Baseline in the Diabetes Symptoms Checklist-Revised (DSC-R) at 12 Weeks and 16 Weeks [ Time Frame: Baseline, 12 weeks, 16 weeks ] [ Designated as safety issue: No ]
    Comprise 6 subscales (34 items). Each item score: 1 (not troublesome) to 5 (extremely troublesome) and transformed to 0-4 scale. Subscale score=sum of item scale in each subscale/total number of items. Global score=sum of scores by dimension. All scores standardized (0-100). Higher scores=greater symptom burden. Study GMAH was terminated after enrolling 78 participants. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure was not analyzed.
  • Mean Total Daily Dose of LY2599506 During the 12-week Treatment Period [ Time Frame: Baseline through 12 weeks ] [ Designated as safety issue: No ]
    The average total daily dose (sum of assigned morning and afternoon doses), in milligrams (mg), at each visit. Study GMAH was terminated after enrolling 78 participants. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure is not presented.
  • Maximum Plasma Concentration (Cmax) at the Steady State for LY2599506 [ Time Frame: Predose and 2 hours after dosing or predose and 4-12 hours after dosing in weeks 1, 2, 3, and 12 ] [ Designated as safety issue: No ]
    The Cmax value measures the maximum plasma concentration at steady state following administration of doses of LY2599506. Due to the nature of the sparse sampling approach, Cmax was estimated using the posthoc pharmacokinetic (PK) parameters obtained from population PK (PopPK) modeling. Study GMAH was terminated after enrolling 78 participants. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure is not presented.
  • Area Under the Concentration-time Curve (AUC) at a Dosing Interval (AUCtau) at the Steady State for LY2599506 [ Time Frame: Predose and 2 hours after dosing or predose and 4-12 hours after dosing in weeks 1, 2, 3, and 12 ] [ Designated as safety issue: No ]
    The AUCtau values measure the area under the plasma concentration time curve at a dosing interval at steady state for LY2599506. Due to the nature of sparse sampling approach taken for the study AUC tau was estimated using the posthoc pharmacokinetic (PK) parameters obtained from population PK (PopPK) modeling. Study GMAH was terminated after enrolling 78 participants. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure was not analyzed.
  • 30-day Adjusted Rates of Self-reported Hypoglycemic Episodes Overall [ Time Frame: Baseline through 16 weeks ] [ Designated as safety issue: Yes ]
    Hypoglycemia: any time a participant experienced a sign/symptom associated with hypoglycemia or had blood glucose <70 milligrams per deciliter (mg/dL) (3.9 millimoles per liter [mmol/L]). The 30-day adjusted rate=(total number of episodes between 2 time intervals/number of days between intervals) X 30 days. Study GMAH was terminated after enrolling 78 participants. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure is not presented.
  • Change From Baseline in Heart Rate at 12 Weeks and 16 Weeks [ Time Frame: Baseline, 12 weeks, 16 weeks ] [ Designated as safety issue: Yes ]
    Heart rate was measured in heartbeats per minute. Study GMAH was terminated after enrolling 78 participants. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure is not presented.
  • Change in QT interval in electrocardiogram from baseline to 12 week and 16 week endpoint [ Time Frame: Baseline, 12 weeks, 16 weeks ] [ Designated as safety issue: Yes ]
  • Change in Homeostasis Model Assessment (HOMA2) from baseline to 12 week and 16 week endpoint [ Time Frame: Baseline, 12 weeks, 16 weeks ] [ Designated as safety issue: No ]
  • Change in triglycerides, LDL, HDL, non-HDL cholesterol, total cholesterol and free fatty acids from baseline to 12 week and 16 week endpoint [ Time Frame: Baseline, 12 weeks, 16 weeks ] [ Designated as safety issue: Yes ]
  • Changes in European Quality of Life -5 dimension (EuroQol-5 dimension) from baseline to 12 week and 16 week endpoint [ Time Frame: Baseline, 12 weeks, 16 weeks ] [ Designated as safety issue: No ]
  • Change in blood pressure [ Time Frame: Baseline to 12 weeks, 16 weeks ] [ Designated as safety issue: Yes ]
  • Incidence of hypoglycemic episodes, categorized by severity and treatment group from baseline, during 12 weeks of treatment, and during 4 weeks of follow-up period [ Time Frame: Baseline, up to 12 weeks and 16 weeks ] [ Designated as safety issue: Yes ]
  • Change in body weight from baseline to 12 week and 16 week endpoint [ Time Frame: Baseline, 12 weeks, 16 weeks ] [ Designated as safety issue: No ]
  • 7 point self-monitored blood glucose (SMBG) [ Time Frame: Baseline, 4 weeks, 12 weeks, 16 weeks ] [ Designated as safety issue: No ]
  • Frequency of patients receiving reduced doses [ Time Frame: Baseline to 12 weeks ] [ Designated as safety issue: No ]
  • Percentage of patients with lipase and amylase measurements by treatment group and study visits above 2-fold upper limits of normal (ULN) [ Time Frame: Baseline to 12 weeks ] [ Designated as safety issue: Yes ]
  • Total and direct bilirubin, Alkaline phosphatase, alanine transaminase (ALT/SGPT), aspartate transaminase (AST/SGOT), gamma-glutamyl transferase (GGT): percentage of patients above 2-, 3-, and 5-fold upper limits of normal (ULN) [ Time Frame: Baseline up to 12 weeks, 16 weeks ] [ Designated as safety issue: Yes ]
  • Changes in Diabetes Treatment Satisfaction Questionnaire from baseline to 12 week and 16 week endpoint [ Time Frame: Baseline, 12 weeks, 16 weeks ] [ Designated as safety issue: No ]
  • Changes in Adult Low Blood Sugar Survey from baseline to 12 week and 16 week endpoint [ Time Frame: Baseline, 12 weeks, 16 weeks ] [ Designated as safety issue: No ]
  • Changes in Diabetes Symptoms Checklist-revised from baseline to 12 week and 16 week endpoint [ Time Frame: Baseline, 12 weeks, 16 weeks ] [ Designated as safety issue: No ]
  • Total daily dose of LY2599506 per visit [ Time Frame: Baseline, 1, 2, 3, 4, 6, 8, 10, 12 weeks ] [ Designated as safety issue: No ]
  • Pharmacokinetics LY2599506 maximum concentration (Cmax) [ Time Frame: Predose and 2 hours after dosing or predose and 4-12 hours after dosing in weeks 1, 2, 3, and 12 ] [ Designated as safety issue: No ]
  • Pharmacokinetics LY2599506 area under the concentration-time curve (AUC) [ Time Frame: Predose and 2 hours after dosing or predose and 4-12 hours after dosing in weeks 1, 2, 3, and 12 ] [ Designated as safety issue: No ]
  • Rate of hypoglycemic episodes per 30 days [ Time Frame: Baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks ] [ Designated as safety issue: Yes ]
  • Change in heart rate [ Time Frame: Baseline to 12 weeks, 16 weeks ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
A Study of LY2599506 in Patients With Type 2 Diabetes
A 12-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of LY2599506 in Patients With Type 2 Diabetes Mellitus Treated With Diet and Exercise, With or Without Metformin

The purpose of this study is to help answer the following questions:

  • To test if taking LY2599506 for 12 weeks controls blood sugar better than taking placebo for 12 weeks.
  • To evaluate the safety of LY2599506 in participants with diabetes.
  • To determine if LY2599506 has the ability to control blood sugar in participants with diabetes.
  • To determine how much LY2599506 should be given to participants.
  • To determine if LY2599506 has an effect on a participant's weight.

The study design consists of 4 study periods: a screening period, a 4-week dose adjustment period, an 8-week treatment period, and a 4-week follow-up period.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Diabetes Mellitus, Type 2
  • Drug: Placebo
    Administered po BID, prior to morning and evening meals for 12 weeks.
  • Drug: LY2599506
    Administered po for 12 weeks
    Other Name: Glucokinase Activator
  • Placebo Comparator: 0 milligrams (mg) Placebo
    Participants received 2 placebo capsules by mouth (po), twice daily (BID), prior to morning and evening meals for 12 weeks.
    Intervention: Drug: Placebo
  • Experimental: 100 mg LY2599506
    Participants received 50-mg capsules of LY2599506 po BID (One 50 mg LY2599506 capsule + 1 matching placebo capsule), prior to morning and evening meals for 12 weeks.
    Intervention: Drug: LY2599506
  • Experimental: 200 mg LY2599506
    Participants received two 50-mg capsules of LY2599506 po BID, prior to morning and evening meals for 12 weeks.
    Intervention: Drug: LY2599506
  • Experimental: 400 mg LY2599506
    Participants received two 100-mg capsules of LY2599506 po BID, prior to morning and evening meals for 12 weeks.
    Intervention: Drug: LY2599506
  • Experimental: 200 mg LY2599506 once daily
    Participants received 200-mg of LY2599506 po once daily (QD) (Two 100 mg LY2599506 capsules prior to morning meal, 2 matching placebo capsules prior to evening meal for 12 weeks).
    Intervention: Drug: LY2599506
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
78
July 2010
July 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Have type 2 diabetes mellitus prior to entering the trial.
  • Are currently being treated with diet and exercise therapy consistent with the local standards of medical care.
  • May be treated with diet and exercise alone or in combination with a stable of metformin for at least 3 month before entering the trial.
  • Have a hemoglobin A1c value between 7.0% and 10.0 %, inclusive.
  • Are women not of child-bearing potential due to surgical sterilization (hysterectomy or bilateral oophorectomy or tubal ligation) or menopause. Male patients will be advised to use a reliable method of birth control during the study and until 3 months after the last dose of study medication if their partner is of child-bearing potential.

Exclusion Criteria:

  • Use of insulin or any antidiabetic agent other than metformin during the 3 months prior entering the trial.
  • Have a gastrointestinal disease that significantly impacts gastric emptying or motility (for example, severe gastroparesis or pyloric stenosis), in the opinion of the investigator, or have undergone gastric bypass or gastric banding surgery.
  • Have had more than 1 episode of severe hypoglycemia within 6 months prior to entry into the study, or are currently diagnosed as having hypoglycemia unawareness.
  • Have had 2 or more emergency room visits or hospitalizations due to poor glucose control in the past 6 months.
  • Have cardiac autonomic neuropathy (for example, resting tachycardia or orthostatic hypotension), based on clinical signs, symptoms, or appropriate diagnostic testing.
  • Have cardiac disease with functional status that is New York Heart Association Class II, III or IV or a history of myocardial infarction, unstable angina, or decompensated congestive heart failure in the past 6 month.
  • Have poorly controlled hypertension (that is, mean systolic blood pressure of greater or equal than 160 mm Hg or mean diastolic blood pressure of greater or equal than 100 mm Hg) history of malignant hypertension, evidence of renal artery stenosis and/or evidence of labile blood pressure including symptomatic postural hypotension. Doses of antihypertensive medications must be stable for 30 days before randomization.
  • Have fed or fasting state hypertriglyceridemia (defined as >6.8 millimoles per liter [mmol/L], 600 milligrams per deciliter [mg/dl]) at screening. If taking lipid-lowering agents, doses of these medications must be stable for 30 days prior to randomization.
  • Have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis, or repeated alanine transaminase (ALT) levels >2.5 times the upper limit of the reference range at screening.
  • Have evidence of a significant active, uncontrolled endocrine or autoimmune abnormality, as judged by the Investigator at screening.
  • Have an active or untreated malignancy or have been in remission from a clinically significant malignancy (other than basal or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years.
  • Have a history of seizure disorder.
Both
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Australia,   Puerto Rico,   Russian Federation,   Spain
 
NCT01024244
12781, I2Q-MC-GMAH
No
Eli Lilly and Company
Eli Lilly and Company
Not Provided
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
Eli Lilly and Company
November 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP